IRIS
MORABITO, FORTUNATO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.107
NA - Nord America 1.081
EU - Europa 647
SA - Sud America 635
AF - Africa 69
OC - Oceania 2
AN - Antartide 1
Totale 4.542
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 997
SG - Singapore 920
BR - Brasile 505
CN - Cina 440
VN - Vietnam 302
IT - Italia 301
HK - Hong Kong 200
DE - Germania 89
KR - Corea 71
FI - Finlandia 59
AR - Argentina 57
GB - Regno Unito 37
MX - Messico 33
BD - Bangladesh 30
CA - Canada 29
RU - Federazione Russa 29
FR - Francia 26
NL - Olanda 25
ZA - Sudafrica 23
AT - Austria 21
IQ - Iraq 21
PK - Pakistan 20
UA - Ucraina 19
EC - Ecuador 17
IN - India 17
ID - Indonesia 15
CO - Colombia 14
PY - Paraguay 13
JP - Giappone 10
EG - Egitto 8
TR - Turchia 8
UZ - Uzbekistan 8
CL - Cile 7
DZ - Algeria 7
JO - Giordania 7
KE - Kenya 7
PE - Perù 7
PL - Polonia 7
VE - Venezuela 7
CR - Costa Rica 6
ET - Etiopia 5
MA - Marocco 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NP - Nepal 4
OM - Oman 4
PA - Panama 4
TN - Tunisia 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
CH - Svizzera 3
GT - Guatemala 3
IL - Israele 3
RO - Romania 3
SA - Arabia Saudita 3
SN - Senegal 3
AL - Albania 2
BG - Bulgaria 2
DK - Danimarca 2
ES - Italia 2
GA - Gabon 2
LT - Lituania 2
MK - Macedonia 2
NO - Norvegia 2
SC - Seychelles 2
SE - Svezia 2
TT - Trinidad e Tobago 2
AQ - Antartide 1
BE - Belgio 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
GY - Guiana 1
HN - Honduras 1
IE - Irlanda 1
JM - Giamaica 1
LB - Libano 1
LY - Libia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
SD - Sudan 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
Totale 4.542
Salva come PNG Salva come JPEG
Città #
Singapore 347
Dallas 228
Hong Kong 199
Florence 154
Boardman 146
Ashburn 134
Ho Chi Minh City 119
Hefei 114
Beijing 93
Seoul 71
Hanoi 56
São Paulo 54
Munich 48
Shanghai 44
Helsinki 38
Los Angeles 33
Sesto Fiorentino 23
New York 22
Noto 22
Rio de Janeiro 21
Washington 19
Milan 18
Santa Clara 16
Guangzhou 15
The Dalles 15
Brooklyn 13
Da Nang 13
Haiphong 13
Vienna 13
Mexico City 12
Montreal 12
Turku 12
Biên Hòa 11
Ogden 11
Baghdad 10
Belo Horizonte 10
Johannesburg 10
Quito 10
Tokyo 10
Atlanta 9
Boston 9
Phoenix 9
Ribeirão Preto 9
Wuhan 9
Amsterdam 8
Brasília 8
Lappeenranta 8
Ninh Bình 8
Amman 7
Catania 7
Fortaleza 7
Karachi 7
London 7
Naaldwijk 7
Nairobi 7
Nuremberg 7
Thái Nguyên 7
Elk Grove Village 6
Guayaquil 6
Recife 6
Rome 6
San Francisco 6
Santo André 6
Tashkent 6
Addis Ababa 5
Campinas 5
Cape Town 5
Charlotte 5
Chicago 5
Curitiba 5
Denver 5
Dhaka 5
Goiânia 5
Porto Alegre 5
Salvador 5
Seattle 5
Warsaw 5
Ankara 4
Belford Roxo 4
Bogotá 4
Bắc Giang 4
Cairo 4
Can Tho 4
Chapecó 4
Ciudad del Este 4
Columbus 4
Falkenstein 4
Feira de Santana 4
Formosa 4
Frankfurt am Main 4
Guarulhos 4
Kyiv 4
La Plata 4
Lahore 4
Maceió 4
Medellín 4
Quảng Ngãi 4
San José 4
Secaucus 4
Sorocaba 4
Totale 2.548
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 143
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 97
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 91
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 90
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 89
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 89
Momelotinib in myelofibrosis 86
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 84
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 82
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 81
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 80
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 79
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 78
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 77
Belantamab mafodotin in multiple myeloma 77
Elotuzumab in multiple myeloma 77
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 76
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 76
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 76
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 75
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 73
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 73
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 73
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 72
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 71
Vaccination in Multiple Myeloma: Challenges and Strategies 70
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 67
Acalabrutinib in chronic lymphocytic leukemia 67
Selinexor in multiple myeloma 66
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 66
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 65
Ivosidenib in acute myeloid leukemia 64
Iron chelation therapy 64
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 63
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 63
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 60
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 60
Teclistamab-cqyv in multiple myeloma 60
Myelodysplastic syndromes with ring sideroblasts 59
The role of corticosteroids in the current treatment paradigm for myelofibrosis 58
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 58
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 58
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 58
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 56
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 56
Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 56
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 54
Avatrombopag for the Treatment of Immune Thrombocytopenia 53
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 53
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 52
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 52
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 52
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period 51
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 51
Zanubrutinib for the treatment of chronic lymphocytic leukemia 51
REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA 51
Glasdegib for the treatment of acute myeloid leukemia 49
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 49
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 46
Tagraxofusp in myeloid malignancies 46
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 44
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 44
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 43
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 42
Isatuximab in multiple myeloma 42
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 42
Mosunetuzumab for the treatment of follicular lymphoma 42
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 41
Venetoclax in acute myeloid leukemia 38
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 36
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia 34
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 28
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 24
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 18
Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization 18
T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions 16
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 7
Totale 4.628
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.900
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.900
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202369 0 0 0 0 0 0 30 4 4 4 21 6
2023/2024599 9 14 121 91 53 90 29 21 20 10 21 120
2024/20251.433 56 112 33 72 68 63 32 67 220 143 146 421
2025/20262.527 504 271 421 341 757 233 0 0 0 0 0 0
Totale 4.628